Search hospitals > New York > New York

Laura and Isaac Perlmutter Cancer Center at NYU Langone

Claim this profile
New York, New York 10016
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Recurrence
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
354 reported clinical trials
44 medical researchers
Photo of Laura and Isaac Perlmutter Cancer Center at NYU Langone in New YorkPhoto of Laura and Isaac Perlmutter Cancer Center at NYU Langone in New YorkPhoto of Laura and Isaac Perlmutter Cancer Center at NYU Langone in New York

Summary

Laura and Isaac Perlmutter Cancer Center at NYU Langone is a medical facility located in New York, New York. This center is recognized for care of Cancer, Tumors, Recurrence, Breast Cancer, Non-Small Cell Lung Cancer and other specialties. Laura and Isaac Perlmutter Cancer Center at NYU Langone is involved with conducting 354 clinical trials across 622 conditions. There are 44 research doctors associated with this hospital, such as Sharon L. Gardner, Bhavana Pothuri, Vamsidhar Velcheti, MD, and Paul Oberstein, MD.

Area of expertise

1Cancer
Global Leader
Laura and Isaac Perlmutter Cancer Center at NYU Langone has run 118 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Tumors
Global Leader
Laura and Isaac Perlmutter Cancer Center at NYU Langone has run 61 trials for Tumors. Some of their research focus areas include:
Stage IV
Stage III
KRAS positive

Top PIs

Clinical Trials running at Laura and Isaac Perlmutter Cancer Center at NYU Langone

Breast Cancer
Cancer
Bladder Cancer
Lung Cancer
Diffuse Large B-Cell Lymphoma
Non-Small Cell Lung Cancer
Lymphoma
Non-Hodgkin's Lymphoma
Squamous Cell Carcinoma
Tumors
Image of trial facility.

Imlunestrant

for Early Breast Cancer

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Recruiting2 awards Phase 36 criteria
Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This study is evaluating whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Laura and Isaac Perlmutter Cancer Center at NYU Langone?
Laura and Isaac Perlmutter Cancer Center at NYU Langone is a medical facility located in New York, New York. This center is recognized for care of Cancer, Tumors, Recurrence, Breast Cancer, Non-Small Cell Lung Cancer and other specialties. Laura and Isaac Perlmutter Cancer Center at NYU Langone is involved with conducting 354 clinical trials across 622 conditions. There are 44 research doctors associated with this hospital, such as Sharon L. Gardner, Bhavana Pothuri, Vamsidhar Velcheti, MD, and Paul Oberstein, MD.
Where is Laura and Isaac Perlmutter Cancer Center at NYU Langone located?
**Laura and Isaac Perlmutter Cancer Center at NYU Langone Health** - **Address:** 160 East 34th Street, New York, NY 10016 - **Designation:** National Cancer Institute-designated Comprehensive Cancer Center - **Focus:** Cutting-edge research, patient care, and community outreach.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Laura and Isaac Perlmutter Cancer Center at NYU Langone, contact the Financial Counselors and Financial Assistance for Hospital Bills department at 718-630-7136. They assist with applications, insurance coverage, and billing concerns for uninsured patients or those with partial insurance coverage. For financial aid related to medical education at NYU Langone Health, reach out to the Office of Admissions and Financial Aid via finaid@nyulangone.org or at 212-263-5286. They manage financial aid for MD students, offering information on scholarships, loans, and other resources.
What insurance does Laura and Isaac Perlmutter Cancer Center at NYU Langone accept?
The Laura and Isaac Perlmutter Cancer Center at NYU Langone accepts various insurance plans. Patients are advised to consult the list of insurance plans NYU Langone participates in to verify coverage and should also check with their doctors to confirm participation in their insurance plan's network. The Perlmutter Cancer Center operates in Manhattan, Brooklyn, Queens, and Long Island; patients should confirm insurance acceptance with their specific facility.
What awards or recognition has Laura and Isaac Perlmutter Cancer Center at NYU Langone received?
The Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, an NCI-Designated Comprehensive Cancer Center, excels in basic science and clinical research, cancer prevention, and the education of researchers and clinicians. It has received a 51% increase in NCI funding, totaling nearly $20 million, and a generous $50 million gift from Laura and Isaac Perlmutter to enhance its research and care efforts. The center's research focuses on cancer cell biology, cancer genome dynamics, tumor immunology, melanoma, and epidemiology and cancer control, promoting translational research and multidisciplinary care.